A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Recruiting · Phase 3 · NCT05254743
Conditions: Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
At a glance
- Research payments reported, 2025
- $1.0M
- U.S. investigators named
- 19
- Sites paid
- 21
- Planned or actual enrollment
- 737
About the trial
- Sponsor
- Loxo Oncology, Inc.
- Tested
- Pirtobrutinib (drug), Ibrutinib (drug)
- Dates
- Started 2022-07-22; completion 2028-01
- Results posted
- Not yet
The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment for their cancer. The purpose of Part 2 of this study evaluates pirtobrutinib monotherapy in treatment-naïve participants with CLL/SLL with 17p deletions. Participation could last up to six years for Part 1. Participation could last up to 2 years for Part 2.
From ClinicalTrials.gov, last updated 2026-08-17. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $1.0M in research payments for this study in 2025 (35 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Richy Agajanian, M.D. Hematology & Oncology · Downey, CA
- Alberto Bessudo, M.D. Hematology & Oncology · Encinitas, CA
- Bita Fakhri, M.D., M.P.H Hematology · Palo Alto, CA
- David Nguyen Student in an Organized Health Care Education/Training Program · Long Beach, CA
- Jennifer L. Cultrera, M.D. Medical Oncology · Lady Lake, FL
- Shachar Peles, M.D. Medical Oncology · Palm Springs, FL
- Mark A. Taylor, M.D. Hematology & Oncology · Savannah, GA
- Michael J. Castine III, MD Medical Oncology · Baton Rouge, LA
- David Morrison, MD Hematology & Oncology · New Orleans, LA
- Bruce D. Cheson, MD Hematology · Bethesda, MD
- Patrick W. Cobb, M.D. Hematology & Oncology · Billings, MT
- Jennifer A. Woyach, MD Hematology · Columbus, OH
- Chanh T. Huynh, MD Hematology & Oncology · York, PA
- Suzanne R. Fanning, D.O. Hematology & Oncology · Greenville, SC
- Bertrand M. Anz III, M.D. Hematology & Oncology · Chattanooga, TN
- Sunil M. Patel, M.D. Hematology · Houston, TX
- Yuvraj Choudhary, M.D. Hematology & Oncology · North Chesterfield, VA
- Arvind Chaudhry, MD Hematology & Oncology · Spokane, WA
- Brett L. Gourley, MD Hematology & Oncology · Spokane, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Sarah Cannon Research Institute LLC $328,504
- The Administrators of the Tulane Educational Fund $113,063
- Cancer Care Associates of York, Inc $75,706
- Pro Research Tools, Inc $71,811
- American Oncology PArtners PA $66,962
- Innovative Clinical Research Institute LLC $60,300
- Helios Cr, Inc. $48,931
- Board of Trustees of the Leland Stanford Jr Univ $41,604
- Qcca Network, LLC $41,255
- Deaconess Medical Center, WA $40,838
- Kelsey Research Foundation $33,236
- Medical Oncology Associates Ps $29,758
- Intermountain Health St Vincent Regional Hospital, MT $20,091
- Tennessee Oncology PLLC $18,575
- Providence Facey Medical Foundation $11,000
- Summit Cancer Care $10,515
- Cancer Car Associates of Fresno Medical Group $8,470
- The Ohio State University $3,657
- Florida Cancer Specialists $907
- Prisma Health Oconee Memorial Hospital, SC $624
- American Oncology PArtners of Maryland PA $189
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.